Duaklir Pressair (aclidinium bromide and formoterol fumarate; Circassia) is now available for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The active ...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), today announced the launch of DUAKLIR® PRESSAIR ...

Circassia, a pharmaceutical company that calls Morrisville home to its U.S. headquarters, received FDA approval for Duaklir Pressair – a drug the treatment of patients with chronic obstructive ...

MISSISSAUGA, ON, Oct. 29, 2015 /CNW/ - AstraZeneca Canada announced today that DUAKLIR ™ GENUAIR ® (aclidinium bromide/formoterol fumarate dihydrate 400/12 μg) is now available in Canada for ...

Patients were randomized equally to placebo, aclidinium bromide monotherapy (Eklira), aclidinium bromide/formoterol fumarate combination therapy (Duaklir), and monotherapy formoterol for a 24-week ...

Duaklir Genuair is a fixed-dose combination of Eklira, a long-acting muscarinic-antagonist, and Mylan, Inc.’s (MYL) Perforomist (formoterol fumarate), a long-acting beta-agonist. Both are ...

Duaklir® is a fixed-dose LAMA / LABA combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate administered twice ...

With the EU approval of COPD med Duaklir, AstraZeneca ($AZN) is getting exactly what it wanted when it sealed a deal for Almirall's respiratory portfolio earlier this ...

LONDON-A trial study using AstraZeneca PLC's (AZN.LN) drug Duaklir has significantly improved lung function in chronic obstructive pulmonary disease or COPD patients, the pharmaceutical company ...

Duaklir® is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate, administered via the Pressair ...